Back to search results

3D Multi-Parametric Ultrasound for Liver Cancer

This study is looking at how well a special type of ultrasound, called 3D Multi-Parametric Ultrasound (3D-MPUS), works to help doctors make decisions for patients with liver cancer. This ultrasound is a safe and inexpensive way to get more information about liver tumors during treatment. You might be able to join if you are an adult (18 or older) with liver cancer that has spread from colorectal cancer and you are planning to start a new cancer treatment. You also need to have at least one tumor that is 1 centimeter or larger. The main goal is to see how much useful information the 3D-MPUS provides right at the beginning of the study. The study is currently unclear on its recruitment status and plans to include about 80 participants.

Study design
This is an observational study, meaning researchers will be watching and collecting information. It aims to include about 80 participants.
What's involved
You will receive an ultrasound scan lasting less than 20 minutes to locate the tumor, followed by the 3D-MPUS acquisition.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05705219

Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients

Recruiting
Not specifiedAges 18+Observational
University of California, San Diego
~80 participants
Updated 2026-01-26 on ClinicalTrials.gov
What's tested:3D-MPUS

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Diagnostic yield of the 3D-MPUS data acquisition
Measured over Baseline visit

Conditions

Liver Cancer, Adult

Explore related trials

Colorectal Carcinoma

Where it's being run

3 sites across 2 states
California2
Pennsylvania1

Study leadership

  • Ahmed El Kaffas, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Diego
  • Aya Kamaya, MD · STUDY_DIRECTOR · Stanford University
  • Andrej Lyshchik, MD, PhD · STUDY_DIRECTOR · Thomas Jefferson University
  • Aman Khurana, MD · STUDY_DIRECTOR · University of California, San Diego
  • Yuko Kono, MD, PhD, FAIUM, FAASLD · STUDY_DIRECTOR · University of California, San Diego

Who to contact

David Marcellus, BS
[email protected]
(650) 723-4547
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Any line of cancer therapy is allowed, including systemic and localized treatments, after any prior treatment. For systemic combination treatments, prior treatment with either drug is allowed at the discretion of the investigators, including rechallenges with the same drug combination, for example upon progression on imaging after a treatment break. For combination treatments where patients start treatment with different drugs at different times, the start date of treatment is determined at the discretion of the investigators and can be the start date of the first drug or of the combination treatment. Repeat participation in the study is allowed, if patients are eligible again per their treatment plan.

Exclusion

Examples: any mental condition that compromises the ability to follow a consent discussion, or to make informed decisions (except if represented by a Legally Authorized Representative \[LAR\]); any condition that makes the participant not a good candidate to have ultrasound exams with contrast agent.

What this trial measures

  • Diagnostic yield of the 3D-MPUS data acquisitionBaseline visit

    Diagnostic yield will be the percentage of non-missing measurements (per reader, per measurement) Participants with successful measurements of the following parameters (following administration of a contrast agent). * peak enhancement (PE)